C9301 Insurance Policy Changes

HCPCS C9301 is officially defined as "Obecabtagene autoleucel, up to 400 million cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose." HCPCS C9301 is referenced in 2 tracked payer policy changes from Blue Cross Blue Shield of Rhode Island and Blue Cross Blue Shield of North Dakota. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS C9301 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Only a small number of policies match this filter. Check back as coverage expands.

Related

All billing codes992129920299213992039920499214

Get alerts for changes like this

Save a search and receive a daily digest whenever a new policy change matches your filters.

Create a free alert